Sanuwave Health, Inc.
SNWVSanuwave Health, Inc. in brief
Sanuwave Health, Inc. is a listed company in the Medical Devices industry, based in Georgia, USA. Its market value was $44 M on 28 October 2026, which makes it the 21,708th largest listed company in the world and the 3,911th largest in the USA on this site. In the year to December 2025 it had sales of $44 M and a net profit of $12 M, about 27 cents of profit for every dollar of sales. It employs about 55 people and Morgan C. Frank is its chief executive. Its largest product and service lines by sales in 2025 were Consumables, parts, and accessories revenue (59%), System revenue (41%) and Extended warranty (under 1%). Its shares trade under the symbol SNWV (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sanuwave Health, Inc.
Sanuwave is a medical device company providing directed energy products into the wound care space. Our mission is to improve patient lives and outcomes by developing and marketing effective, easy to use products to decrease wound burden, lessen healing times, and reduce patient pain.
Our focus is regenerative medicine utilizing noninvasive ultrasound to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The Company’s patented and FDA cleared product is the UltraMIST® system, which is used to treat a variety of acute and chronic wounds. The Company is backed by an intellectual property portfolio of over 60 patents.
From the company's annual report filed with the US SEC: read the report
Sanuwave Health, Inc. timeline
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2010
- ✎Renamed SANUWAVE Health, Inc.Formerly Rub Music Enterprises, Inc..
- 2025
- 💰Record revenue of $44 millionFY2025, the highest of the 8 years on record.
Events of Sanuwave Health, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,662 (Jan 2022) · #1,710 (Mar 2026) · #3,795 (Aug 2026) · #3,862 (Oct 2026) · #3,915 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 10.6×
- Price / sales (TTM)
- 1.1×
- Price / book
- 27.2×
- Free cash flow yield
- 4.4%
- Net margin (TTM)
- 10.0%
- Operating margin
- 11.2%
- Return on equity
- 256.2%
- Liabilities / assets
- 95.7%
- Net debt
- $10M
- Revenue growth
- +35.0%
- R&D / revenue
- 3.1%
- Revenue per employee
- $801 K
- Profit per employee
- $215 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $44M | +35.0% | $5M | $12M | 26.8% |
| Dec 2024 | $33M | +60.0% | $4M | $-33M | -101.4% |
| Dec 2023 | $20M | +21.9% | $-1M | $-26M | -126.5% |
| Dec 2022 | $17M | +28.7% | $-9M | $-10M | -61.5% |
| Dec 2021 | $13M | +220.4% | $-14M | $-27M | -209.5% |
| Dec 2020 | $4M | +165.4% | $-25M | $-31M | -762.1% |
| Dec 2019 | $2M | -17.3% | $-9M | $-10M | -681.7% |
| Dec 2018 | $2M | — | $-7M | $-12M | -628.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $4M | $2M | $2M | $0.41 | — |
| Dec 2024 | $2M | $0M | $2M | $-7.41 | — |
| Dec 2023 | $-5M | $0M | $-5M | $-12.19 | — |
| Dec 2022 | $-17M | — | — | $-0.02 | — |
| Dec 2021 | $-6M | $1M | $-7M | $-0.05 | — |
| Dec 2020 | $-13M | $0M | $-13M | $-0.08 | — |
| Dec 2019 | $-6M | $0M | $-6M | $-0.05 | — |
| Dec 2018 | $-4M | $0M | $-4M | $-0.08 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $9M (-23.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Oct 28, 20268-KCurrent reportMaterial agreement
- Sep 25, 20268-KCurrent reportListing notice
- Aug 6, 20268-KCurrent reportResults of operations
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Jul 13, 20268-KCurrent reportResults of operations
- Jun 16, 20268-KCurrent reportRegulation FD disclosure
- Jun 15, 20268-KCurrent reportShareholder vote
- May 12, 20268-KCurrent reportResults of operations
- May 12, 202610-QQuarterly report · period to Mar 2026
- Apr 29, 2026DEF 14AProxy statement
Official filings of Sanuwave Health, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $44 M
- Operating income
- $5 M
- Net income
- $12 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $37 M
- Total liabilities
- $36 M
- Total equity
- $2 M
As of December-2025
Top 40 institutional investors in Sanuwave Health, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Solas Capital Management, LLC | 610,968 | 0 (0.00%) | 7.10% | $3 M | Nov 16, 2026 |
| 2 | AWM Investment Company, Inc. | 427,765 | -26,785 (-5.89%) | 4.97% | $2 M | Nov 13, 2026 |
| 3 | Vanguard Capital Management LLC | 348,050 | -4,706 (-1.33%) | 4.05% | $2 M | Nov 13, 2026 |
| 4 | Opaleye Management Inc. | 306,140 | 0 (0.00%) | 3.56% | $1 M | Nov 16, 2026 |
| 5 | UBS Group AG | 162,089 | -94,702 (-36.88%) | 1.88% | $1 M | Nov 10, 2026 |
| 6 | BlackRock, Inc. | 142,973 | -16,894 (-10.57%) | 1.66% | $1 M | Nov 13, 2026 |
| 7 | Geode Capital Management, LLC | 89,704 | +3,606 (+4.19%) | 1.04% | $0 M | Nov 6, 2026 |
| 8 | D. E. Shaw & Co., Inc. | 59,338 | New | 0.69% | $0 M | Nov 16, 2026 |
| 9 | Luxor Capital Group, LP | 58,299 | +21,099 (+56.72%) | 0.68% | $0 M | Nov 16, 2026 |
| 10 | Vanguard Fiduciary Trust Co | 54,862 | +11,765 (+27.30%) | 0.64% | $0 M | Nov 13, 2026 |
| 11 | Jpmorgan Chase & Co | 50,107 | +10,410 (+26.22%) | 0.58% | $0 M | Nov 12, 2026 |
| 12 | State Street Corp | 31,282 | -1,000 (-3.10%) | 0.36% | $0 M | Nov 12, 2026 |
| 13 | Morgan Stanley | 30,446 | -1,173 (-3.71%) | 0.35% | $0 M | Nov 13, 2026 |
| 14 | XTX Topco Ltd | 29,282 | +7,448 (+34.11%) | 0.34% | $0 M | Nov 16, 2026 |
| 15 | Gsa Capital Partners LLP | 28,452 | New | 0.33% | $0 M | Nov 16, 2026 |
| 16 | State of Alaska, Department of Revenue | 28,235 | +25,000 (+772.80%) | 0.33% | $0 M | Oct 15, 2026 |
| 17 | Invesco Ltd. | 25,573 | New | 0.30% | $0 M | Nov 12, 2026 |
| 18 | Goldman Sachs Group Inc | 24,583 | -15,843 (-39.19%) | 0.29% | $0 M | Nov 16, 2026 |
| 19 | Citadel Advisors LLC | 23,050 | -36,423 (-61.24%) | 0.27% | $0 M | Nov 16, 2026 |
| 20 | Squarepoint Ops LLC | 21,243 | +3,000 (+16.44%) | 0.25% | $0 M | Nov 9, 2026 |
| 21 | Bank Of America Corp /de/ | 18,570 | +11 (+0.06%) | 0.22% | $0 M | Nov 16, 2026 |
| 22 | Northern Trust Corp | 16,454 | 0 (0.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 23 | BNP Paribas Financial Markets | 15,019 | +1,715 (+12.89%) | 0.17% | $0 M | Nov 12, 2026 |
| 24 | Millennium Management LLC | 10,282 | -6,643 (-39.25%) | 0.12% | $0 M | Nov 16, 2026 |
| 25 | Praetorian PR LLC | 8,453 | -386,547 (-97.86%) | 0.10% | $0 M | Nov 16, 2026 |
Show all 40: investors 26 to 40
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Cullinan Associates Inc | 4,200 | New | 0.05% | $0 M | Nov 3, 2026 |
| 27 | Vanguard Global Advisers, LLC | 3,237 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 28 | FMR LLC | 2,849 | -1,605 (-36.04%) | 0.03% | $0 M | Nov 10, 2026 |
| 29 | Russell Investments Group, Ltd. | 2,327 | +2,278 (+4648.98%) | 0.03% | $0 M | Nov 6, 2026 |
| 30 | Strategic Investment Solutions, Inc. /IL | 1,333 | 0 (0.00%) | 0.02% | $0 M | Nov 12, 2026 |
| 31 | Acuitas Investments, LLC | 1,000 | New | 0.01% | $0 M | Nov 6, 2026 |
| 32 | Royal Bank Of Canada | 413 | +264 (+177.18%) | 0.00% | $0 M | Nov 16, 2026 |
| 33 | WealthCollab, LLC | 410 | New | 0.00% | $0 M | Nov 12, 2026 |
| 34 | ABS Investment Management LLC | 400 | New | 0.00% | $0 M | Nov 16, 2026 |
| 35 | Arax Advisory Partners | 291 | -355 (-54.95%) | 0.00% | $0 M | Nov 12, 2026 |
| 36 | Physician Wealth Advisors, Inc. | 245 | New | 0.00% | $0 M | Oct 20, 2026 |
| 37 | US Bancorp \de\ | 66 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 38 | NewEdge Advisors, LLC | 26 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 39 | Osaic Holdings, Inc. | 12 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 40 | IFP Advisors, Inc | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
Mutual funds holding Sanuwave Health, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 264,933 | $3 M | 4.0% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 78,885 | $1 M | 1.2% | <0.01% | +5.2% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 38,422 | $1 M | 0.58% | <0.01% | +4.8% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 36,377 | $1 M | 0.55% | <0.01% | −1.5% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 26,001 | $0 M | 0.39% | 0.02% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,580 | $0 M | 0.20% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 10,764 | $0 M | 0.16% | <0.01% | +7.4% | May 31, 2026 |
| 🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P. | 9,750 | $0 M | 0.15% | 0.02% | +1.3% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 7,105 | $0 M | 0.11% | <0.01% | +3.0% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 10,000 | $0 M | 0.15% | 0.07% | no change | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 9,271 | $0 M | 0.14% | <0.01% | +141% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 5,459 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 4,706 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 2,852 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 4,232 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 3,564 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,747 | $0 M | 0.03% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 1,000 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 2,389 | $0 M | 0.04% | <0.01% | −0.3% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 1,432 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 611 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 1,454 | $0 M | 0.02% | <0.01% | +41% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 350 | $0 M | <0.01% | <0.01% | +8.4% | May 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 940 | $0 M | 0.01% | <0.01% | +1.8% | Jul 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 501 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 300 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 274 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 276 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 230 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 271 | $0 M | <0.01% | <0.01% | −57% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 175 | $0 M | <0.01% | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 171 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 46 | $0 M | <0.01% | <0.01% | +4.5% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 33 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sanuwave Health, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Opaleye Management Inc.10% owner | Sellindirect | -10,081 | $16.11 | $162 K | 853,569 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -500 | $16.11 | $8 K | 5,000 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -24,000 | $16.15 | $388 K | 863,650 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -1,000 | $16.15 | $16 K | 5,500 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -23,360 | $17.25 | $403 K | 887,650 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -1,000 | $17.25 | $17 K | 6,500 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -43,788 | $18.47 | $809 K | 911,010 | Form 4 |
| filed | Opaleye Management Inc.10% owner | Sellindirect | -2,500 | $18.47 | $46 K | 7,500 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sanuwave Health, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-370.37 reverse split
Trading halts
- 2026-11-05 14:56 UTC, code LUDP, resumed 15:06 UTC
- 2026-11-05 14:41 UTC, code LUDP, resumed 14:51 UTC
- 2026-11-05 14:31 UTC, code LUDP, resumed 14:36 UTC
Fails to deliver
- : 12 shares at $5.13
- : 15 shares at $5.54
- : 65 shares at $4.10
- : 45 shares at $4.45
- : 970 shares at $5.03
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sanuwave Health, Inc. scorecard#
Passes 15 of the 22 checks that could be worked out: strongest in growth (6 of 6), weakest in financial health (2 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation3 of 5
- ✓P/E below its peers' median10.6×P/E 10.6× against Medical Devices's median of 24.1×.
- ✗Price to book below its peers' median27.2×Price to book 27.2× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median1.1×Price to sales 1.1× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%4.4%Free cash flow is 4.4% of the market value.
- ✓Earnings yield above the 10-year Treasury yield9.4%Earnings yield 9.4% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth6 of 6
- ✓Revenue grew in the newest year35.0%Revenue up 35.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years38.1%38.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median38.1%38.1% a year against Medical Devices's median of 10.8% (73 companies).
- ✓Earnings per share grew in the newest year0.41 vs -7.41Diluted EPS 0.41 in fiscal 2025 against -7.41 the year before (report's currency).
- ✓Net income higher than five years earlier$12 M$12 M in fiscal 2025 against -$31 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability4 of 5
- ✓Profitable in the newest year$12 MNet income $12 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median11.2%11.2% against Medical Devices's median of -8.2% (86 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- ✓Return on invested capital above 10%42.5%42.5% in fiscal 2025.
- ✓Operating margin wider than three years earlier11.2%11.2% in fiscal 2025 against -53.5% in 2022.
Financial health2 of 5
- ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.38 at the end of fiscal 2025.
- ✗Debt below equity13.5×Debt to equity 13.51 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDA1.7×Net debt 1.7 times EBITDA in fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-6.52Z-score -6.52 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year103.5%Diluted shares up 103.5% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Sanuwave Health, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 11.2% | -8.2% | |
| Net margin | 26.8% | -10.4% | |
| Revenue growth, 3 years a year | 38.1% | 10.8% | |
| Revenue growth | 35.0% | 10.4% | |
| Debt to equity | 13.51× | 0.64× | |
| Free cash flow margin | 4.4% | -1.9% |
6of 8on the Piotroski tests of financial strength
- Only 33% of net income arrived as cash from operations.
- The share count rose 103.5% in the year.
- Receivables grew 63% while revenue grew 35%: customers are paying later, or sales were booked ahead of cash.
- Goodwill and intangibles ($10 million) exceed shareholders' equity ($2 million).
Sanuwave Health, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 44+35.0%100% | 33+60.0%100% | 20+21.8%100% | 17+28.7%100% | 13+221%100% | 4.1r4.1+165%100% | 1.5−17.4%100% | 1.9+151%100% | 0.7−46.3%100% | 1.4—100% | |
| Cost of revenue | 10+24.7%22.9% | 8.1+34.0%24.8% | 6.0+39.3%29.6% | 4.3−13.1%25.9% | 5.0+329%38.3% | 1.2r1.2+116%28.6% | 0.5−22.3%35.3% | 0.7+187%37.5% | 0.2−57.2%32.8% | 0.6—41.1% | |
| Gross profit | 34+38.4%77.1% | 25+70.9%75.2% | 14+15.7%70.4% | 12+54.7%74.1% | 8.0+177%61.7% | 2.9r2.9+491%71.4% | 0.5r1.0−57.6%32.0% | 1.2+133%62.5% | 0.5—67.2% | — | |
| Research and development | 1.4+101%3.1% | 0.7+16.2%2.1% | 0.6+2.1%2.8% | 0.6−48.5%3.4% | 1.1−11.6%8.5% | 1.2r1.2+5.4%30.7% | 1.2+20.4%77.3% | 1.0r1.7−24.1%53.1% | 1.3+14.5%175% | 1.1—82.0% | |
| Selling and marketing | 7.4+17.3%16.8% | 6.3+29.1%19.4% | 4.9−34.5%24.0% | 7.5−13.0%44.6% | 8.6+66.5%66.0% | 5.2r5.2+224%127% | 1.6+205%104% | 0.5—28.2% | — | — | |
| General and administrative | 19+50.0%44.0% | 13r11+48.9%39.6% | 8.7−30.9%42.5% | 13+7.4%75.0% | 12−14.8%89.9% | 14r14+113%338% | 6.4−5.4%421% | 6.8r6.7+127%368% | 3.0+12.4%407% | 2.7—194% | |
| Operating expenses | 29+40.2%65.9% | 21r19+38.9%63.4% | 15−30.2%73.1% | 21−3.6%128% | 22−21.1%170% | 28r28+203%693% | 9.3+11.4%607% | 8.3+92.9%451% | 4.3+4.7%585% | 4.1—300% | |
| Total costs and expenses | 0.6+22.4%1.3% | 0.5−0.4%1.5% | 0.5+49.4%2.4% | 0.3−14.1%1.9% | 0.4—2.9% | — | — | — | — | — | |
| Operating income | 4.9+28.5%11.2% | 3.8r5.4—11.8% | −0.5—−2.6% | −9.0—−53.5% | −14—−109% | −25r−25—−621% | −8.8r−8.3—−575% | −7.2—−388% | −3.8—−518% | −3.3—−241% | |
| Interest expense and finance costs | — | 13—38.5% | — | 13+85.5%76.3% | 6.9+240%52.9% | 2.0r2.0+10.3%49.9% | 1.8−59.2%120% | 4.5+294%243% | 1.1r1.0+33.3%154% | 0.9—62.1% | |
| Other non-operating income (expense) | 7.0—15.8% | −37r−37—−113% | −25—−124% | −1.3—−8.0% | −13—−101% | −5.7r−5.7—−141% | −1.6—−107% | −4.5—−241% | −1.7—−232% | −3.1—−227% | |
| Income before tax | 12—27.0% | −33—−101% | — | — | — | — | — | — | — | — | |
| Income tax | 0.1+219%0.2% | 0.0+575%0.1% | 0.0+100%0.0% | 0.0−92.9%0.0% | 0.0—0.2% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | 12—26.8% | −33r−31—−101% | −26—−127% | −10—−61.5% | −27—−210% | −31r−31—−763% | −10r−9.9—−682% | −12—−629% | −5.5—−750% | −6.4—−468% | |
| Earnings per share, basic | 1.38—— | -7.41r-7.03—— | -12.19r-0.03—— | -0.02—— | -0.05—— | -0.08—— | -0.05—— | -0.08—— | -0.04—— | -0.06—— | |
| Earnings per share, diluted | 0.41—— | -7.41r-7.03—— | -12.19r-0.03—— | -0.02—— | -0.05—— | -0.08—— | -0.05—— | -0.08—— | -0.04—— | -0.06—— | |
| Shares, weighted average (basic) | 8.6+91.9%— | 4.5+111%— | 2.1r794−99.6%— | 549+6.0%— | 518+37.1%— | 378+85.7%— | 204—— | — | — | — | |
| Shares, weighted average (diluted) | 9.1+104%— | 4.5+111%— | 2.1r794−99.6%— | 549+6.0%— | 518+37.1%— | 378+85.7%— | 204r203+36.1%— | 150+7.7%— | 139+29.0%— | 108—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 12+16.8%32.0% | 10+470%34.0% | 1.8+55.9%8.0% | 1.2+86.3%5.8% | 0.6−74.6%3.3% | 2.4r2.4+38.4%10.6% | 1.8+383%52.1% | 0.4−50.1%31.0% | 0.7+447%57.1% | 0.1—13.3% | |
| Receivables | 5.4+62.9%14.5% | 3.3+0.5%11.1% | 3.3−17.7%14.8% | 4.0+66.8%20.3% | 2.4+2.5%13.0% | 2.4r2.4+3019%10.2% | 0.1−67.8%2.2% | 0.2+53.9%19.9% | 0.2−66.9%11.9% | 0.5—45.9% | |
| Inventory | 5.9+43.0%15.9% | 4.1+40.6%13.8% | 3.0+240%13.2% | 0.9−16.5%4.4% | 1.0−64.8%5.6% | 3.0r3.0+444%12.8% | 0.5+51.7%16.1% | 0.4+54.5%30.4% | 0.2−0.2%18.1% | 0.2—23.1% | |
| Other current assets | 1.3+92.4%3.5% | 0.7−60.4%2.3% | 1.7+202%7.7% | 0.6+74.8%2.9% | 0.3+82.1%1.8% | 0.2r0.2+42.7%0.8% | 0.1—3.7% | — | — | — | |
| Current assets | 25+33.9%65.9% | 18+88.0%61.1% | 9.8+47.8%43.6% | 6.6+50.5%33.3% | 4.4−44.5%23.6% | 7.9r7.9+217%34.4% | 2.5+131%74.0% | 1.1−10.0%92.0% | 1.2+31.8%94.2% | 0.9—91.0% | |
| Property, plant and equipment | 2.0+551%5.3% | 0.3r0.7−67.7%1.0% | 0.9+9.6%4.2% | 0.9r0.8−15.4%4.3% | 1.0r0.7+115%5.4% | 0.5r0.5+401%2.0% | 0.1r0.5+20.8%2.8% | 0.1+28.8%6.6% | 0.1−21.5%4.7% | 0.1—7.7% | |
| Right-of-use (leased) assets | 0.4−9.1%1.0% | 0.4—1.4% | — | — | 0.2−60.9%0.8% | 0.4r0.7−18.9%1.7% | 0.5r0.3—14.1% | 0—0.0% | — | — | |
| Goodwill | 7.30.0%19.4% | 7.30.0%24.1% | 7.30.0%32.4% | 7.30.0%36.5% | 7.30.0%39.0% | 7.3r7.3—31.5% | 0—0.0% | — | — | — | |
| Other intangible assets | 3.0−18.9%8.1% | 3.7−15.9%12.4% | 4.4−13.7%19.8% | 5.1−12.1%25.8% | 5.8−10.8%31.4% | 6.5—28.4% | — | — | — | — | |
| Non-current assets | 13+8.5%34.1% | 12−7.2%38.9% | 13−4.7%56.4% | 13−6.8%66.7% | 14—76.4% | — | — | — | — | — | |
| Total assets | 37+24.0%100% | 30+34.4%100% | 22+12.8%100% | 20+6.7%100% | 19−19.1%100% | 23r23+581%100% | 3.4+187%100% | 1.2−7.9%100% | 1.3+27.3%100% | 1.0—100% | |
| Accounts payable | 3.3−12.8%8.7% | 3.7−34.7%12.4% | 5.7+29.7%25.5% | 4.4−42.4%22.1% | 7.6+71.6%41.1% | 4.5r4.5+209%19.3% | 1.4−9.6%42.6% | 1.6+6.4%135% | 1.5+110%117% | 0.7—71.0% | |
| Debt due within a year | 5.8—15.4% | — | — | — | 25+53.0%136% | 17—72.1% | — | — | — | — | |
| Current liabilities | 18−60.7%47.8% | 45r42−29.9%151% | 65+7.5%289% | 60r60+7.0%303% | 56+55.5%302% | 36r36+191%157% | 12r12−24.7%367% | 16+47.7%1400% | 11r11+41.0%873% | 7.9—788% | |
| Long-term debt | 16—43.2% | — | — | — | 0.9+512%4.7% | 0.1—0.6% | — | — | — | — | |
| Lease liabilities (non-current) | 0.9—2.3% | — | — | — | 0.1−53.2%0.4% | 0.2r0.2−15.0%0.7% | 0.2—5.5% | 0—0.0% | — | — | |
| Non-current liabilities | 18+3541%47.9% | 0.5−41.5%1.6% | 0.8+25.6%3.7% | 0.7r0.7−49.2%3.4% | 1.3+130%7.1% | 0.6r0.6−44.6%2.5% | 1.0r0.5+2104%30.5% | 0.0—4.0% | 0—0.0% | — | |
| Total liabilities | 36−22.2%95.7% | 46r43−30.0%152% | 66+7.7%293% | 61+5.7%306% | 58+56.7%309% | 37r37+173%160% | 13r13−18.7%398% | 17+48.2%1404% | 11r11+41.0%873% | 7.9—788% | |
| Retained earnings | −243—−650% | −254r−251—−845% | −220—−982% | −194—−977% | −184—−988% | −157r−157—−680% | −126r−125—−3718% | −117—−9901% | −105r−105—−8209% | −99—−9895% | |
| Shareholders' equity | 1.6—4.3% | −16r−13—−52.4% | −45r−43—−199% | −41—−206% | −39—−209% | −14r−14—−59.6% | −10r−9.6—−298% | −15—−1304% | −9.9r−9.8—−773% | −6.9—−688% | |
| Total liabilities and equity | 37+24.0%100% | 30+34.4%100% | 22+12.8%100% | 20+6.7%100% | 19−19.1%100% | 23r23+581%100% | 3.4+187%100% | 1.2−7.9%100% | 1.3+27.3%100% | 1.0—100% | |
| Shares outstanding | 8.6+0.5%— | 8.5+181%— | 3.0r1,141−99.4%— | 549+13.9%— | 482+2.3%— | 471+60.2%— | 294+88.7%— | 156+11.7%— | 139+1.5%— | 137—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.0+23.6%2.2% | 0.8r1.1−23.3%2.4% | 1.0+8.0%5.0% | 1.0−23.0%5.7% | 1.2r0.5+313%9.5% | 0.3r0.3+320%7.4% | 0.1—4.7% | — | — | — | |
| Share-based compensation | 4.9+220%11.0% | 1.5—4.6% | 0—0.0% | — | 0−100%0.0% | 0.0r0.0−93.4%0.5% | 0.3−86.6%21.8% | 2.5+223%134% | 0.8+40.2%104% | 0.5—39.8% | |
| Cash from operating activities | 3.9+57.9%8.8% | 2.5—7.5% | −4.5—−22.2% | −17—−103% | −6.4—−49.3% | −13r−13—−313% | −6.4—−419% | −3.6—−196% | −1.5—−207% | −3.2—−233% | |
| Capital expenditure | −1.9—−4.4% | −0.5—−1.5% | 0—0.0% | — | −0.5—−4.1% | −0.1r−0.1—−1.3% | −0.1—−3.5% | −0.0—−2.3% | 0—0.0% | −0.0—−0.8% | |
| Cash from investing activities | 3.4—7.8% | −0.5−2433%−1.5% | 0.0−93.7%0.1% | 0.3—2.0% | −0.5—−4.1% | −20r−20—−494% | −0.1—−3.5% | −0.0—−2.3% | 0—0.0% | −0.0—−0.6% | |
| Debt repaid | — | — | 0—0.0% | −3.0—−17.8% | −0.5—−3.8% | −5.5r−5.5—−135% | 0—0.0% | — | — | — | |
| Shares issued | 0−100%0.0% | 10—31.6% | 0—0.0% | — | — | — | — | — | — | — | |
| Cash from financing activities | −5.6−188%−12.7% | 6.4+21.9%19.5% | 5.2−70.0%25.5% | 17+239%104% | 5.1−84.7%39.4% | 33r33+326%824% | 7.9+137%514% | 3.3+56.7%179% | 2.1−34.0%287% | 3.2—233% | |
| Exchange-rate effect on cash | 0−100%0.0% | 0.1—0.4% | −0.1—−0.2% | −0.0—−0.1% | −0.0—−0.0% | 0r−0.0−100%0.0% | 0.0—0.0% | −0.0−330%−1.0% | 0.0—1.1% | −0.0—−1.4% | |
| Change in cash | 1.7−79.6%3.9% | 8.4+1211%25.9% | 0.6+20.6%3.2% | 0.5—3.2% | −1.8−369%−14.0% | 0.7r0.7−51.6%16.7% | 1.4—91.3% | −0.4−161%−19.8% | 0.6—80.8% | −0.0—−1.4% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 41+0.8%100% | 8.6−23.9%100% | 9.7−3.1%100% | 9.6+3.1%100% | 13*+29.7%100% | 11r11+20.4%100% | 10r10+40.4%100% | 9.3r9.3+61.3%100% | 10*+47.6%100% | 9.4—100% | 7.2—100% | 5.8—100% | 7.0*—100% | |
| Cost of revenue | 9.8+9.7%23.8% | 2.0−22.8%22.7% | 2.3+4.9%23.8% | 2.2+11.7%22.7% | 3.4*+48.4%25.3% | 2.5+10.2%22.4% | 2.2+14.8%21.9% | 2.0+23.6%21.0% | 2.3*+5.8%22.1% | 2.3—24.5% | 1.9—26.8% | 1.6—27.4% | 2.2*—30.9% | |
| Gross profit | 31−1.6%76.2% | 6.6−24.2%77.3% | 7.4−5.4%76.2% | 7.4+0.8%77.3% | 10*+24.4%74.7% | 8.7r8.9+23.7%77.6% | 7.8r8.0+49.8%78.1% | 7.4r7.4+75.5%79.0% | 8.0*+66.3%77.9% | 7.1—75.5% | 5.2—73.2% | 4.2—72.6% | 4.8*—69.1% | |
| Research and development | 2.3+157%5.6% | 0.4+23.5%5.0% | 0.6+224%6.4% | 0.7+217%6.9% | 0.6*+294%4.5% | 0.3+114%3.1% | 0.2−0.5%1.9% | 0.2+27.6%2.2% | 0.2*+7.7%1.5% | 0.2—1.7% | 0.2—2.7% | 0.2—2.8% | 0.1*—2.0% | |
| Selling and marketing | 8.3+16.6%20.1% | 1.9−10.2%21.8% | 1.9+14.9%19.7% | 2.4+56.7%24.9% | 2.1*+15.0%15.9% | 2.1−5.5%18.5% | 1.7+61.9%16.7% | 1.5+24.3%16.4% | 1.9*+26.4%18.0% | 2.2—23.5% | 1.0—14.4% | 1.2—21.3% | 1.5*—21.0% | |
| General and administrative | 20+11.3%49.0% | 5.1−1.2%59.8% | 4.9+12.2%50.3% | 5.3+8.4%54.6% | 5.0*+30.8%37.1% | 5.2r4.8+72.2%46.1% | 4.4r4.0+100%43.4% | 4.8r4.5+23.6%51.9% | 3.8r3.3*+90.3%36.8% | 3.0r2.5—32.2% | 2.2r1.8—30.5% | 3.9r3.7—67.7% | 2.0*—28.5% | |
| Operating expenses | 32+18.1%77.3% | 7.7−1.8%89.8% | 7.7+20.2%79.1% | 8.6+26.3%88.9% | 8.0*+32.7%59.7% | 7.8r7.5+40.4%69.6% | 6.4r6.1+78.4%63.8% | 6.8r6.4+23.3%72.6% | 6.0r5.5*+58.8%58.4% | 5.6r5.1—59.7% | 3.6r3.2—50.2% | 5.5r5.3—95.0% | 3.8*—54.3% | |
| Operating income | −0.5−110%−1.1% | −1.1−219%−12.5% | −0.3−119%−2.9% | −1.1−287%−11.7% | 2.0*−0.4%15.0% | 0.9r1.5−39.1%8.0% | 1.4r1.9−12.7%14.3% | 0.6r1.0—6.4% | 2.0r2.5*+93.6%19.5% | 1.5r2.0—15.8% | 1.6r2.0—23.0% | −1.3r−1.1—−22.4% | 1.0*—14.9% | |
| Interest expense and finance costs | — | 0.3−84.6%3.2% | 0.5−73.3%5.3% | 0.5−71.4%5.7% | — | 1.8−46.5%15.9% | 1.9−43.4%19.3% | 1.9−41.5%20.5% | 2.5*—24.4% | 3.4—35.8% | 3.4—47.8% | 3.3—56.4% | — | |
| Other non-operating income (expense) | 4.8—11.6% | −0.3−103%−3.3% | −0.4—−4.1% | −0.3—−3.3% | 5.8*—43.1% | 8.8r8.9—78.0% | −0.9r−0.8−120%−8.8% | −6.7r−6.7—−72.0% | −15r−15*−189%−148% | −23r−23—−242% | 4.5r4.6—63.4% | −3.5r−3.5—−60.6% | 17*—246% | |
| Income tax | — | 0.1—0.7% | 0.0—0.1% | — | 0.1*—0.6% | 0—0.0% | 0—0.0% | — | — | — | — | — | 0.0*—0.1% | |
| Net income attributable to shareholders | 4.2—10.1% | −1.4−115%−16.5% | −0.7−224%−7.0% | −1.4—−15.0% | 7.7*—57.4% | 9.7r10—86.0% | 0.6r1.1−91.1%5.5% | −6.1r−5.7—−65.6% | −13r−13*−173%−129% | −21r−21—−226% | 6.2r6.6—86.4% | −4.8r−4.5—−82.9% | 18*—261% | |
| Earnings per share, basic | — | -0.16−114%— | -0.08−233%— | -0.17—— | — | 1.13r1.20—— | 0.06r0.12+500%— | -0.72r-0.66—— | — | -6.65r-6.49—— | 0.01r0.01—— | 0.00r0.00—— | — | |
| Earnings per share, diluted | — | -0.16−141%— | -0.08—— | -0.17—— | — | 0.39r0.46—— | -0.04r0.01—— | -0.72r-0.66—— | — | -6.65r-6.49—— | 0.00r0.00—— | 0.00r0.00—— | — | |
| Shares, weighted average (basic) | 8.6+0.4%— | 8.6+0.4%— | 8.6+0.5%— | 8.6+0.5%— | — | 8.6+169%— | 8.6+172%— | 8.5+176%— | — | 3.2r3.2—— | 3.2r1,183—— | 3.1r1,162—— | — | |
| Shares, weighted average (diluted) | 8.6−5.9%— | 8.6−5.9%— | 8.6−6.2%— | 8.6+0.5%— | — | 9.1+187%— | 9.2+148%— | 8.5+176%— | — | 3.2r3.2—— | 3.7r1,388—— | 3.1r1,162—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 6.6—20.2% | 6.6−31.6%20.2% | 9.4+10.4%25.6% | 11+26.8%29.1% | 12+16.8%32.0% | 9.6+195%27.0% | 8.5+245%25.7% | 8.5+190%27.6% | 10+470%34.0% | 3.3—14.9% | 2.5—11.7% | 2.9—12.6% | 1.8—8.0% | |
| Receivables | 5.0—15.3% | 5.0+7.5%15.3% | 5.8+50.8%15.8% | 6.0+55.2%16.2% | 5.4+62.9%14.5% | 4.6+62.9%13.0% | 3.8+22.0%11.6% | 3.9+28.5%12.5% | 3.3+0.5%11.1% | 2.8—13.0% | 3.2—15.0% | 3.0—12.9% | 3.3—14.8% | |
| Inventory | 6.7—20.7% | 6.7−1.3%20.7% | 7.1+19.6%19.3% | 5.9+8.2%15.9% | 5.9+43.0%15.9% | 6.8+98.6%19.1% | 5.9+116%17.9% | 5.5+122%17.7% | 4.1+40.6%13.8% | 3.4—15.7% | 2.7—13.0% | 2.5—10.6% | 3.0—13.2% | |
| Other current assets | 1.0—3.1% | 1.0−37.3%3.1% | 1.0−50.1%2.6% | 1.3+26.5%3.4% | 1.3+92.4%3.5% | 1.6+322%4.5% | 1.9+405%5.8% | 1.0−58.5%3.3% | 0.7−60.4%2.3% | 0.4—1.7% | 0.4—1.8% | 2.4—10.4% | 1.7—7.7% | |
| Current assets | 19—59.3% | 19−14.7%59.3% | 23+15.0%63.4% | 24+27.2%64.6% | 25+33.9%65.9% | 23+129%63.6% | 20+131%61.0% | 19+73.9%61.0% | 18+88.0%61.1% | 9.9—45.3% | 8.7—41.5% | 11—46.4% | 9.8—43.6% | |
| Property, plant and equipment | 2.4—7.2% | 2.4+17.9%7.2% | 2.3+42.1%6.2% | 1.9+326%5.2% | 2.0+551%5.3% | 2.0+158%5.6% | 1.6+67.6%4.8% | 0.4−53.9%1.5% | 0.3r0.7−67.7%1.0% | 0.8—3.5% | 0.9—4.5% | 1.0—4.2% | 0.9—4.2% | |
| Right-of-use (leased) assets | 0.9—2.8% | 0.9+112%2.8% | 1.0+45.9%2.6% | 1.0+30.2%2.7% | 0.4−9.1%1.0% | 0.4—1.2% | 0.7—2.0% | 0.8—2.5% | 0.4—1.4% | — | — | — | — | |
| Goodwill | 7.3—22.3% | 7.30.0%22.3% | 7.30.0%19.8% | 7.30.0%19.6% | 7.30.0%19.4% | 7.30.0%20.4% | 7.30.0%22.0% | 7.30.0%23.5% | 7.30.0%24.1% | 7.3—33.2% | 7.3—34.6% | 7.3—31.1% | 7.3—32.4% | |
| Other intangible assets | 2.7—8.3% | 2.7−15.7%8.3% | 2.9−14.5%7.9% | 2.9−17.9%7.9% | 3.0−18.9%8.1% | 3.2−18.0%9.0% | 3.4−17.2%10.2% | 3.6−16.5%11.5% | 3.7−15.9%12.4% | 3.9—17.9% | 4.1—19.4% | 4.3—18.3% | 4.4—19.8% | |
| Non-current assets | 13—40.7% | 13+2.0%40.7% | 13+4.1%36.6% | 13+9.3%35.4% | 13+8.5%34.1% | 13+8.6%36.4% | 13+4.8%39.0% | 12−3.8%39.0% | 12−7.2%38.9% | 12—54.7% | 12—58.5% | 12—53.6% | 13—56.4% | |
| Total assets | 33—100% | 33−8.6%100% | 37+10.8%100% | 37+20.2%100% | 37+24.0%100% | 36+63.0%100% | 33+57.3%100% | 31+32.3%100% | 30+34.4%100% | 22—100% | 21—100% | 23—100% | 22—100% | |
| Accounts payable | 3.2—9.7% | 3.2−21.1%9.7% | 3.3−17.3%9.0% | 3.3−20.0%8.9% | 3.3−12.8%8.7% | 4.0−3.5%11.2% | 4.0+2.9%12.1% | 4.2−18.0%13.5% | 3.7−34.7%12.4% | 4.1—18.9% | 3.9—18.5% | 5.1—21.7% | 5.7—25.5% | |
| Debt due within a year | — | — | — | 5.8—15.5% | 5.8—15.4% | 5.8—16.2% | — | — | — | — | — | — | — | |
| Current liabilities | 16—50.4% | 16−31.6%50.4% | 18−64.0%49.6% | 18−64.0%49.3% | 18−60.7%47.8% | 24r20−70.6%67.4% | 50r47−15.9%153% | 51r47−27.6%165% | 45r42−29.9%151% | 82—373% | 60—285% | 70—301% | 65—289% | |
| Long-term debt | — | — | — | 15—39.8% | 16—43.2% | 18—49.3% | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 1.4—4.4% | 1.4—4.4% | — | — | 0.9—2.3% | — | — | — | — | — | — | — | — | |
| Non-current liabilities | 13—40.8% | 13−29.9%40.8% | 16+1085%42.7% | 17+1829%45.7% | 18+3541%47.9% | 19+3091%53.2% | 1.3+102%4.0% | 0.9+19.6%2.8% | 0.5−41.5%1.6% | 0.6—2.7% | 0.7—3.1% | 0.7—3.2% | 0.8—3.7% | |
| Total liabilities | 30—91.2% | 30−31.3%91.2% | 34−34.8%92.4% | 35−31.8%95.0% | 36−22.2%95.7% | 43r39−47.4%121% | 52r48−14.5%157% | 52r48−27.1%167% | 46r43−30.0%152% | 82—376% | 61—288% | 71—304% | 66—293% | |
| Retained earnings | −246—−757% | −246—−757% | −245—−669% | −244—−658% | −243—−650% | −250r−246—−703% | −260r−256—−787% | −261r−257—−845% | −254r−251—−845% | −239—−1093% | −218—−1038% | −225—−963% | −220—−982% | |
| Shareholders' equity | 2.9—8.8% | 2.9—8.8% | 2.8—7.6% | 1.8—5.0% | 1.6—4.3% | −7.6r−2.9—−21.3% | −19r−15—−56.9% | −21r−17—−67.5% | −16r−13—−52.4% | −60—−276% | −40—−188% | −48—−204% | −45r−43—−199% | |
| Total liabilities and equity | 33—100% | 33−8.6%100% | 37+10.8%100% | 37+20.2%100% | 37+24.0%100% | 36+63.0%100% | 33+57.3%100% | 31+32.3%100% | 30+34.4%100% | 22—100% | 21—100% | 23—100% | 22—100% | |
| Shares outstanding | 8.6—— | 8.6+0.3%— | 8.6+0.4%— | 8.6+0.5%— | 8.6+0.5%— | 8.6+172%— | 8.6−99.3%— | 8.5−99.3%— | 8.5+181%— | 3.2—— | 1,181—— | 1,141—— | 3.0r1,141—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.2+40.8%2.8% | 0.3+23.4%3.2% | 0.3+44.3%2.6% | 0.3+40.7%3.1% | 0.3*+56.0%2.5% | 0.2+7.8%2.0% | 0.2−3.3%1.7% | 0.2+53.7%2.2% | 0.2r0.4*−12.1%2.1% | 0.2—2.2% | 0.2—2.5% | 0.1r0.2—2.4% | 0.2*—3.5% | |
| Share-based compensation | 6.0+19.6%14.5% | 1.5+5.9%17.3% | 1.6+38.9%16.1% | 1.6+65.2%16.7% | 1.3*−11.7%10.0% | 1.4—12.4% | 1.1—11.3% | 1.0—10.4% | 1.5*—14.7% | 0*—0.0% | 0*—0.0% | 0—0.0% | — | |
| Cash from operating activities | 3.3+153%8.0% | −0.9*−179%−9.9% | 0.4*−57.2%4.4% | 0.4—4.1% | 3.3*+348%24.8% | 1.1*−15.7%9.6% | 1.0*—9.9% | −1.5−238%−16.3% | 0.7*—7.2% | 1.3*—13.7% | −0.7*—−9.3% | 1.1—19.0% | −1.3*—−18.4% | |
| Capital expenditure | −0.7—−1.7% | −0.2*—−2.8% | −0.3*—−3.4% | −0.0—−0.2% | −0.1*—−0.7% | −0.5*—−4.7% | −1.2*—−11.5% | −0.2—−1.7% | −0.2*—−2.3% | −0.0*—−0.5% | −0.1*—−1.3% | −0.1—−2.0% | — | |
| Cash from investing activities | −0.5−118%−1.3% | −0.2*−105%−2.4% | −0.4*—−4.6% | −0.2—−1.6% | 0.3*—2.1% | 4.5*—39.7% | −1.2*—−11.5% | −0.2—−1.7% | −0.2*−233%−2.3% | −0.0*—−0.5% | −0.1*—−1.3% | −0.1—−2.0% | 0.2*—2.5% | |
| Cash from financing activities | −5.8−372%−14.0% | −1.8*—−20.4% | −1.4*−957%−14.2% | −1.4—−14.8% | −1.2*−119%−9.3% | −4.5*—−39.5% | 0.2*−41.2%1.6% | −0.1−236%−0.6% | 6.5*+249%62.7% | −0.4*—−4.6% | 0.3*—3.8% | 0.0—0.7% | 1.9*—26.5% | |
| Exchange-rate effect on cash | — | — | — | 0—0.0% | 0*—0.0% | 0*—0.0% | 0*−100%0.0% | 0−100%0.0% | 0*—0.0% | 0*—0.0% | 0.0*—0.1% | 0.1—1.9% | −0.0*—−0.6% | |
| Change in cash | −3.0−148%−7.3% | −2.8*−354%−32.7% | −1.4*—−14.4% | −1.2—−12.3% | 2.4*−66.2%17.6% | 1.1*+38.4%9.8% | −0.0*—−0.0% | −1.7−252%−18.6% | 7.0*+894%67.6% | 0.8*—8.5% | −0.5*—−6.6% | 1.1—19.7% | 0.7*—10.0% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Sanuwave Health, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Consumables, parts, and accessories revenue$26 M59%+22%
- System revenue$18 M41%+61%
- Other$0 M0.5%-32%
- Extended warranty$0 M0.4%+70%
- License fees$0 M0.1%-50%
Business segments
- Reportable$44 M100%+35%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Sanuwave Health, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Morgan C. Frank | $414 K | $1.6 M | $1.3 M | $349 |
| 2024Morgan C. Frank | $1.4 M | $2.6 M | $1.0 M | $269 |
| 2023Morgan C. Frank | $410 K | $410 K | $329 K | $57 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Sanuwave Health, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 1 · Financial statements withdrawn 1 · Auditor changed 3 · Directors and officers 6 · Material agreement 3 · Agreement ended 1 · New debt 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawn | 8-K | |
| Shareholder vote | 8-K/A | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Material agreementAgreement endedNew debt | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K/A | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2024 | $2 M | Private placement after listing | Under $2 million | 9 | debt, options | SEC |
| Jan 2024 | $5 M | Private placement after listing | $2 to $10 million | 19 | debt, options | SEC |
| Dec 2023 | $2 M | Private placement after listing | Under $2 million | 15 | debt, options | SEC |
| Jul 2023 | $3 M | Private placement after listing | $2 to $10 million | 17 | debt, options | SEC |
| May 2023 | $1 M | Private placement after listing | Under $2 million | 11 | debt, options | SEC |
| Nov 2022 | $4 M | Private placement after listing | $2 to $10 million | 32 | debt, options | SEC |
| Aug 2022 | $16 M | Private placement after listing | $10 to $50 million | 46 | debt, options | SEC |
| Aug 2020 | $25 M | Private placement after listing | $10 to $50 million | 46 | equity, options | SEC |
| Nov 2017 | $3 M | Private placement after listing | $2 to $10 million | 42 | debt, options | SEC |
| Mar 2014 | $9 M | Private placement after listing | $2 to $10 million | 10 | equity, options | SEC |
| Apr 2011 | $9 M | No. 1 | $2 to $10 million | 28 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How Sanuwave Health, Inc. compares in Medical Devices
- Market cap$44 M · higher than 24% of 142
- Revenue$44 M · higher than 27% of 155
- Net margin10.0% · higher than 71% of 144
- Revenue growth35.0% · higher than 86% of 104
- P/E ratio10.6× · lower than 89% of 47
- Price / sales1.1× · lower than 80% of 96
- Price / book27.2× · lower than 4% of 99
- FCF yield4.4% · higher than 84% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sanuwave Health, Inc.🇺🇸 | $44 M | 10.6× | 10.0% | +35.0% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sanuwave Health, Inc.? Verify and update this profile — free
Show Sanuwave Health, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.